[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@PDUFA_Pulse PDUFA Pulse

PDUFA Pulse posts on X about $mdgl, $galt, $akro, ash the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

• X Week XXX -XX%
• X Month XXXXXX -XX%
• X Months XXXXXX +852%
• X Year XXXXXX +71%

Mentions: X #

• X Week XX -XX%
• X Month XX -XX%
• X Months XX +963%
• X Year XX +571%

Followers: XXX #

• X Week XXX +4.70%
• X Month XXX +30%
• X Months XXX +157%
• X Year XXX +159%

CreatorRank: undefined #

Social Influence

Social category influence cryptocurrencies XXXXX% stocks XXXX%

Social topic influence $mdgl 6.67%, $galt 6.67%, $akro 6.67%, ash 6.67%, $kura 6.67%, $beam 6.67%, $agio 6.67%, alpha 6.67%, agio 6.67%, $dna XXXX%

Top accounts mentioned or mentioned by @runlolarn

Top assets mentioned Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Akropolis (AKRO) BEAM (BEAM) Agios Pharmaceuticals, Inc. (AGIO) Muhdo Hub (DNA) Johnson & Johnson (JNJ)

Top Social Posts

Top posts by engagements in the last XX hours

"Nov XX - $MDGL Rezdiffra (resmetirom MASH) PoA XX % The NASH kingpin reports again. Phase X follow-ups for Rezdiffra. $XX B cap $XXX M cash burn. $GALT $AKRO"
X Link 2025-11-10T18:35Z XXX followers, XXX engagements

"🧬 Forget the Santa Rally its ASH Season. The American Society of Hematology (ASH) meeting kicks off this weekend (Dec 6-9) and the abstracts are already moving markets. While we watch the PDUFA calendar keep an eye on data readouts from $KURA (Kura Oncology) and $BEAM (Beam Therapeutics). The focus this year is heavily on Menin inhibitors and next-gen gene editing for Sickle Cell"
X Link 2025-12-02T19:00Z XXX followers, XXX engagements

"PDUFA TODAY: Agios $AGIO Pyrukynd Label Expansion (/-thalassemia) The Analyst View: Agios is testing the regulatory ceiling for its hematology franchise. While approval probabilities are high (directional 70%) the real alpha lies in the label language. A narrow indicationor a label burdened with restrictive surveillancewill cap the commercial ramp. The Market Structure Risk: Entering the second liquid week of December we are in a "Repricing Vacuum." Institutional bids thin out daily. In this structure failure (CRL) triggers an air-pocket decline while success (Approval) often faces muted"
X Link 2025-12-07T15:58Z XXX followers, 1295 engagements

"Ginkgo Bioworks $DNA just secured a $47M contract from the U.S. Department of Energy to build the countrys first fully autonomous AI-powered microbial labs This is part of the Genesis Mission push to accelerate biofuels sustainable materials and next-gen therapeutics using robotics + AI. From years months for strain engineering Possibly a game-changing infrastructure move"
X Link 2025-12-09T22:10Z XXX followers, XXX engagements

"Just in from ASH 2025: J&Js Tecvayli + Darzalex combo is showing a flattened OS curve in relapsed multiple myeloma. A potential functional cure signal in XX% of patients after X years. Biggest myeloma advance in decades. $JNJ"
X Link 2025-12-10T12:41Z XXX followers, XXX engagements

"📰Roche just dropped blockbuster Phase X data for its oral SERD in early breast cancer: XX% lower risk of recurrence or death vs standard endocrine therapy. First big oral alternative to injectables in decades. $RHHBY $ROG.SW This ones going to move the needle in HR+ breast cancer treatment"
X Link 2025-12-10T20:53Z XXX followers, XXX engagements